ArticleDiscover oncology2025
Antiproliferative and apoptotic activity of a Zn(II) complex against cancer cells, both in vitro and in vivo.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundChemotherapy remains one of the principal treatment strategies in cancer treatment, is widely used but often limited by the development of chemoresistance and adverse side effects.
aimsThis study aimed to develop highly effective chemotherapeutic agents with minimal or no adverse effects, specifically focusing on synthesizing a diisothiocyanatozinc(II) complex, [Zn(L
methodsThe compound's in vitro anticancer activity was assessed against MCF7 cells using cell growth inhibition, apoptotic morphological observation, and gene expression analysis. In vivo antitumor properties of the compound were assayed in Swiss albino mice bearing EAC cells by monitoring key parameters such as tumor burden, survival rate, tumor cell proliferation, and hematological profiles. Toxicity was evaluated through biochemical, hematological, and histological assessments in mice.
resultsThe compound demonstrated dose-dependent growth (11-85%) inhibition at 20-500 µg/mL doses against MCF7 cells. Compound-treated cells showed apoptotic body formation under fluorescent and phase-contrast microscopes. Notably, mRNA expressions of proapoptotic genes such as p53, Bax, PARP1, Caspase-3, -8, -9, etc., were upregulated while anti-apoptotic genes such as Bcl2 were downregulated in compound-treated cells. Also, the compound showed 83% and 86% inhibition of tumor cell proliferation at doses of 100 and 200 µg/kg/day, respectively, compared to the control group of EAC-bearing mice (p < 0.001). Mice treated with 200 µg/kg/day showed a 60.3% increase in mean survival time compared to untreated controls (p < 0.001). Hematological parameters (RBC, WBC, hemoglobin), which were significantly reduced in EAC-bearing control mice, were restored to near-normal levels in treated mice. Transient alterations in hematological and biochemical parameters (serum glucose, cholesterol, creatinine, SGOT, SGPT) were observed during treatment; however, they normalized post-treatment, indicating minimal host toxicity. The compound also demonstrated a low LC
conclusionThe [Zn(L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.